

<b>Reference:</b>	FOI.9763.22
<b>Subject:</b>	Breast Cancer treatments
<b>Date of Request:</b>	31 August 2022

**Requested:**

1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

- Abemaciclib (Verzenio) + aromatase inhibitor \*
  - Abemaciclib (Verzenio) + Fulvestrant (Faslodex)
  - Alpelisib (Piqray) + Fulvestrant (Faslodex)
  - Atezolizumab (Tecentriq)\*\*
  - Bevacizumab (Avastin)
  - Eribulin (Halaven)
  - Everolimus (Afinitor) + Exemestane
  - Fulvestrant (Faslodex) as a single agent
  - Gemcitabine + paclitaxel
  - Herceptin (Trastuzumab) + paclitaxel
  - Herceptin (Trastuzumab) as a single agent
  - Lapatinib (Tyverb)
  - Neratinib (Nerlynx)
  - Olaparib (Lynparza)
  - Palbociclib (Ibrance) + aromatase inhibitor\*
  - Palbociclib (Ibrance) + Fulvestrant (Faslodex)
  - Pertuzumab (Perjeta) + trastuzumab + docetaxel
  - Ribociclib (Kisqali) + aromatase inhibitor\*
  - Ribociclib (Kisqali) + Fulvestrant (Faslodex)
  - Talazoparib (Talzenna)
  - Trastuzumab emtansine (Kadcyla)
  - Other active systemic anti-cancer therapy \*\*
- \*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
- \*\*eg. docetaxel, vinorelbine or capecitabine as a single agent

2. For the above patients, how many of these received their first ever dose for each product line?

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare Team, which holds a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records, to establish the type of cancer diagnosed and therapies used to treat the patients. It is estimated that

conducting this search would take longer than the 18 hours 'appropriate limit' as stated within the Freedom of Information Act 2000 (FoIA).

The UHB is therefore applying an exemption under Section 12 of the FoIA, which provides an exemption from a public authority's obligation to comply with a request for information, where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. We therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB, who may be able to help you with your enquiry. The contact details are as follows:-

[FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk) or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.